The standard international prognostic index for predicting the risk of CNS involvement in DLBCL without specific prophylaxis

Leuk Lymphoma. 2018 Jan;59(1):97-104. doi: 10.1080/10428194.2017.1330541. Epub 2017 Jun 8.

Abstract

Central nervous system (CNS) involvement is a serious complication in patients with diffuse large B-cell lymphoma (DLBCL) and evaluating CNS risk is an important issue. Using the standard international prognostic index (IPI) and CNS-IPI, a recently proposed model including IPI risk factors and adrenal/kidney involvement, we assessed CNS risk in 1220 untreated DLBCL patients who received R-CHOP without prophylaxis. According to the standard IPI, the cumulative incidences of CNS involvement at 2 years were 1.3, 4.6, 8.8, and 12.7% in the low-, low-intermediate-, high-intermediate-, and high-risk groups, respectively (p <.001). This result is comparable with that of the CNS-IPI. Patients with breast involvement tended to have lower risk according to the standard IPI but showed frequent CNS involvement, similar to patients with testis involvement. The standard IPI is also a useful predictor of CNS involvement. Patients with breast/testis involvement would be candidates for prophylaxis regardless of the standard IPI risk.

Keywords: International prognostic index; R-CHOP; central nervous system; diffuse large B-cell lymphoma; prophylaxis.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Combined Chemotherapy Protocols
  • Central Nervous System Neoplasms / epidemiology
  • Central Nervous System Neoplasms / mortality*
  • Central Nervous System Neoplasms / prevention & control
  • Central Nervous System Neoplasms / secondary*
  • Cyclophosphamide
  • Doxorubicin
  • Female
  • Humans
  • Incidence
  • Lymphoma, Large B-Cell, Diffuse / drug therapy
  • Lymphoma, Large B-Cell, Diffuse / epidemiology
  • Lymphoma, Large B-Cell, Diffuse / mortality*
  • Lymphoma, Large B-Cell, Diffuse / pathology*
  • Male
  • Middle Aged
  • Prednisone
  • Prognosis
  • Risk
  • Rituximab
  • Vincristine
  • Young Adult

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • R-CHOP protocol
  • Rituximab
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone